The P2 Purinoceptors in Prostate Cancer

Overview

Journal Purinergic Signal

Publisher Springer

Date 2022 Jun 30

PMID 35771310

Authors

Zilin Wang

Sha Zhu

Sirui Tan

Yuhao Zeng

Hao Zeng

Affiliations

Soon will be listed here.

Abstract

P2 purinoceptors are composed of ligand-gated ion channel type (P2X receptor) and G protein-coupled metabolite type (P2Y receptor). Both these receptors have played important roles in the prostate cancer microenvironment in recent years. P2X and P2Y receptors can contribute to prostate cancer's growth and invasiveness. However, the comprehensive mechanisms have yet to be identified. By summarizing the relevant studies, we believe that P2X and P2Y receptors play a dual role in cancer cell growth depending on the prostate cancer microenvironment and different downstream signalling pathways. We also summarized how different signalling pathways contribute to tumor invasiveness and metastasis through P2X and P2Y receptors, focusing on understanding the specific mechanisms led by P2X4, P2X7, and P2Y2. Statins may reduce and prevent tumor progression through P2X7 so that P2X purinergic receptors may have clinical implications in the management of prostate cancer. Furthermore, P2X7 receptors can aid in the early detection of prostate cancer. We hope that this review will provide new insights for future mechanistic and clinical investigations into the role of P2 purinergic receptors in prostate cancer.

Citing Articles

Reduction of Prostate Cancer Risk: Role of Frequent Ejaculation-Associated Mechanisms.

Hassan M, Flanagan T, Eshaq A, Altamimi O, Altalag H, Alsharif M Cancers (Basel). 2025; 17(5).

PMID: 40075690 PMC: 11898507. DOI: 10.3390/cancers17050843.

Persistent Activation of the P2X7 Receptor Underlies Chronic Inflammation and Carcinogenic Changes in the Intestine.

Santana P, de Lima I, Silva E Souza K, Barbosa P, de Souza H Int J Mol Sci. 2024; 25(20).

PMID: 39456655 PMC: 11507540. DOI: 10.3390/ijms252010874.

The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer.

Gardani C, Diz F, Donde L, Rockenbach L, Laufer S, Morrone F Front Immunol. 2024; 15:1455469.

PMID: 39355246 PMC: 11442216. DOI: 10.3389/fimmu.2024.1455469.

The functional role of P2 purinergic receptors in the progression of gastric cancer.

Zou F, Liu J, Zuo C, He P, Ye J, Zhang W Purinergic Signal. 2024; .

PMID: 38470513 DOI: 10.1007/s11302-024-10000-7.

Whole-exome sequencing identifies cancer-associated variants of the endo-lysosomal ion transport channels in the Saudi population.

Binobaid L, As Sobeai H, Alhazzani K, AlAbdi L, Alwazae M, Alotaibi M Saudi Pharm J. 2024; 32(3):101961.

PMID: 38313820 PMC: 10832475. DOI: 10.1016/j.jsps.2024.101961.

References

Qiu Y, Li W, Zhang H, Liu Y, Tian X, Fang W . P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS One. 2014; 9(12):e114371. PMC: 4259308. DOI: 10.1371/journal.pone.0114371. View

Hattori M, Gouaux E . Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature. 2012; 485(7397):207-12. PMC: 3391165. DOI: 10.1038/nature11010. View

Calvert R, Shabbir M, Thompson C, Mikhailidis D, Morgan R, Burnstock G . Immunocytochemical and pharmacological characterisation of P2-purinoceptor-mediated cell growth and death in PC-3 hormone refractory prostate cancer cells. Anticancer Res. 2004; 24(5A):2853-9. View

Cornford P, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2020; 79(2):263-282. DOI: 10.1016/j.eururo.2020.09.046. View

Di Virgilio F, Falzoni S, Giuliani A, Adinolfi E . P2 receptors in cancer progression and metastatic spreading. Curr Opin Pharmacol. 2016; 29:17-25. DOI: 10.1016/j.coph.2016.05.001. View

Slater M, Danieletto S, Gidley-Baird A, Teh L, Barden J . Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology. 2004; 44(3):206-15. DOI: 10.1111/j.0309-0167.2004.01798.x. View

Ghalali A, Wiklund F, Zheng H, Stenius U, Hogberg J . Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis. 2014; 35(7):1547-55. DOI: 10.1093/carcin/bgu019. View

Amoroso F, Falzoni S, Adinolfi E, Ferrari D, Di Virgilio F . The P2X7 receptor is a key modulator of aerobic glycolysis. Cell Death Dis. 2012; 3:e370. PMC: 3434661. DOI: 10.1038/cddis.2012.105. View

Shorning B, Dass M, Smalley M, Pearson H . The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci. 2020; 21(12). PMC: 7350257. DOI: 10.3390/ijms21124507. View

10.

Graner M . Extracellular vesicles in cancer immune responses: roles of purinergic receptors. Semin Immunopathol. 2018; 40(5):465-475. DOI: 10.1007/s00281-018-0706-9. View

11.

Di Virgilio F, Ferrari D, Adinolfi E . P2X(7): a growth-promoting receptor-implications for cancer. Purinergic Signal. 2009; 5(2):251-6. PMC: 2686832. DOI: 10.1007/s11302-009-9145-3. View

12.

Burnstock G, Di Virgilio F . Purinergic signalling and cancer. Purinergic Signal. 2013; 9(4):491-540. PMC: 3889385. DOI: 10.1007/s11302-013-9372-5. View

13.

Solini A, Simeon V, Derosa L, Orlandi P, Rossi C, Fontana A . Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients. Oncotarget. 2015; 6(30):28743-54. PMC: 4745689. DOI: 10.18632/oncotarget.4926. View

14.

Tafani M, Schito L, Pellegrini L, Villanova L, Marfe G, Anwar T . Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis. 2011; 32(8):1167-75. DOI: 10.1093/carcin/bgr101. View

15.

Slater M, Danieletto S, Barden J . Expression of the apoptotic calcium channel P2X7 in the glandular epithelium. J Mol Histol. 2005; 36(3):159-65. DOI: 10.1007/s10735-004-6166-7. View

16.

Ceder Y, Bjartell A, Culig Z, Rubin M, Tomlins S, Visakorpi T . The Molecular Evolution of Castration-resistant Prostate Cancer. Eur Urol Focus. 2017; 2(5):506-513. DOI: 10.1016/j.euf.2016.11.012. View

17.

Sui X, Kong N, Ye L, Han W, Zhou J, Zhang Q . p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett. 2013; 344(2):174-9. DOI: 10.1016/j.canlet.2013.11.019. View

18.

Hu L, Zhang X, Jiang S, Tao L, Li Q, Zhu L . Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis. Clin Cancer Res. 2018; 25(4):1318-1330. DOI: 10.1158/1078-0432.CCR-18-2297. View

19.

Erb L, Weisman G . Coupling of P2Y receptors to G proteins and other signaling pathways. Wiley Interdiscip Rev Membr Transp Signal. 2015; 1(6):789-803. PMC: 4358762. DOI: 10.1002/wmts.62. View

20.

Bukhari M, Deng H, Jones N, Towne Z, Woodworth C, Samways D . Selective permeabilization of cervical cancer cells to an ionic DNA-binding cytotoxin by activation of P2Y receptors. FEBS Lett. 2015; 589(13):1498-504. PMC: 4497545. DOI: 10.1016/j.febslet.2015.04.044. View